S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:AMPH

Amphastar Pharmaceuticals Stock Forecast, Price & News

$19.19
-0.07 (-0.36 %)
(As of 10/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.10
$19.41
50-Day Range
$17.83
$20.32
52-Week Range
$16.91
$21.63
Volume103,698 shs
Average Volume189,814 shs
Market Capitalization$921.73 million
P/E Ratio91.39
Dividend YieldN/A
Beta0.74
30 days | 90 days | 365 days | Advanced Chart
Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Amphastar Pharmaceuticals logo

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMPH
Employees
1,980
Year Founded
N/A

Sales & Book Value

Annual Sales
$349.85 million
Cash Flow
$1.20 per share
Book Value
$9.45 per share

Profitability

Net Income
$1.40 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$921.73 million
Next Earnings Date
11/5/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.40 out of 5 stars

Medical Sector

179th out of 1,359 stocks

Pharmaceutical Preparations Industry

77th out of 666 stocks

Analyst Opinion: 2.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -












Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

Is Amphastar Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amphastar Pharmaceuticals stock.
View analyst ratings for Amphastar Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Amphastar Pharmaceuticals?

Wall Street analysts have given Amphastar Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amphastar Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Amphastar Pharmaceuticals
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its quarterly earnings results on Sunday, August, 8th. The company reported $0.21 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.21. The company had revenue of $101.66 million for the quarter, compared to the consensus estimate of $101.38 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 8.01% and a net margin of 2.72%.
View Amphastar Pharmaceuticals' earnings history
.

How has Amphastar Pharmaceuticals' stock been impacted by Coronavirus?

Amphastar Pharmaceuticals' stock was trading at $15.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMPH stock has increased by 25.4% and is now trading at $19.19.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AMPH?

2 analysts have issued twelve-month price targets for Amphastar Pharmaceuticals' shares. Their forecasts range from $20.00 to $23.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $21.50 in the next year. This suggests a possible upside of 12.0% from the stock's current price.
View analysts' price targets for Amphastar Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the following people:

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (0.53%), Assenagon Asset Management S.A. (0.37%), State of Alaska Department of Revenue (0.06%), Nisa Investment Advisors LLC (0.06%), Louisiana State Employees Retirement System (0.04%) and Strs Ohio (0.01%). Company insiders that own Amphastar Pharmaceuticals stock include David Maris, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends for Amphastar Pharmaceuticals
.

Which institutional investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Nisa Investment Advisors LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, and Yakob Liawatidewi.
View insider buying and selling activity for Amphastar Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, State of Alaska Department of Revenue, Louisiana State Employees Retirement System, and Strs Ohio.
View insider buying and selling activity for Amphastar Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $19.19.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals has a market capitalization of $921.73 million and generates $349.85 million in revenue each year. The company earns $1.40 million in net income (profit) each year or $0.64 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals employs 1,980 workers across the globe.

What is Amphastar Pharmaceuticals' official website?

The official website for Amphastar Pharmaceuticals is www.amphastar.com.

Where are Amphastar Pharmaceuticals' headquarters?

Amphastar Pharmaceuticals is headquartered at 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at (909) 980-9484 or via email at [email protected].


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.